Prothrombin complex concentrate (PCC) for treatment of trauma-induced coagulopathy: systematic review and meta-analyses
Authors' conclusion
Among published studies of TIC, PCCs did not significantly reduce mortality, nor did they increase the risk of VTE.
Study context
- Population
- Adult major trauma patients with trauma-induced coagulopathy (excluding pediatric, traumatic brain injury (TBI)-only and anticoagulated-only studies)9 observational studies, 1 randomized controlled trial (RCT)
- Comparison
- PCC vs no PCC
- PCCn = 1,150
- Outcome
- In-hospital mortality and venous thromboembolism (VTE)
Methodological detailsrandom-effects model, GRADE assessment
- Random-effects model
- GRADE assessment
Pooled result
As reported in the abstract
In-hospital mortality
Mortality, pooled OR, 8 observational studies
0.97
95% CI 0.56–1.69
Mortality, pooled OR, observational studies and the RCT
0.94
95% CI 0.60–1.45
Safety
- Deep venous thrombosis (DVT), pooled OR, 5 observational studies
- 0.83 [95% CI 0.44-1.57]
- DVT, pooled OR, observational studies and the RCT
- 1.00 [95% CI 0.64-1.55]
Original publication
Prothrombin complex concentrate (PCC) for treatment of trauma-induced coagulopathy: systematic review and meta-analyses. Crit Care. Published 2 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →